Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

LivaNova (LIVN) Research & Development (2016 - 2025)

Historic Research & Development for LivaNova (LIVN) over the last 12 years, with Q3 2025 value amounting to $48.6 million.

  • LivaNova's Research & Development fell 46.72% to $48.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $176.9 million, marking a year-over-year decrease of 454.38%. This contributed to the annual value of $182.5 million for FY2024, which is 583.18% down from last year.
  • Latest data reveals that LivaNova reported Research & Development of $48.6 million as of Q3 2025, which was down 46.72% from $47.2 million recorded in Q2 2025.
  • LivaNova's 5-year Research & Development high stood at $52.6 million for Q2 2021, and its period low was $34.2 million during Q2 2022.
  • For the 5-year period, LivaNova's Research & Development averaged around $44.7 million, with its median value being $44.9 million (2022).
  • In the last 5 years, LivaNova's Research & Development soared by 10895.75% in 2021 and then plummeted by 3487.26% in 2022.
  • LivaNova's Research & Development (Quarter) stood at $44.1 million in 2021, then increased by 1.89% to $44.9 million in 2022, then grew by 2.74% to $46.2 million in 2023, then fell by 6.19% to $43.3 million in 2024, then grew by 12.17% to $48.6 million in 2025.
  • Its Research & Development was $48.6 million in Q3 2025, compared to $47.2 million in Q2 2025 and $37.9 million in Q1 2025.